Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Lisocabtagene Maraleucel→

Lisocabtagene Maraleucel PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2101314-96-7
Molecular formula
Not available
Molecular weight
Not available
Drug class
CD19-directed autologous chimeric antigen receptor (CAR) T-cell immunotherapy
Mechanism of action
Autologous CD4-positive and CD8-positive T cells are genetically modified to express an anti-CD19 chimeric antigen receptor containing 4-1BB costimulatory and CD3-zeta signalling domains. After infusion, the cells recognise CD19-expressing B-lineage tumour cells and mediate T-cell activation, proliferation and cytotoxic killing.
Indications / reported uses
  • Treatment of adults with specified large B-cell lymphomas, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B, in the treatment settings defined by the current product label.
  • The current US label includes selected earlier-line and later-line settings; primary central nervous system lymphoma is not an indicated use.

Sources: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi · https://www.ema.europa.eu/en/medicines/human/EPAR/breyanzi · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lisocabtagene-maraleucel · DailyMed

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

CD19-directed autologous chimeric antigen receptor (CAR) T-cell immunotherapy

Mechanism of action

Autologous CD4-positive and CD8-positive T cells are genetically modified to express an anti-CD19 chimeric antigen receptor containing 4-1BB costimulatory and CD3-zeta signalling domains. After infusion, the cells recognise CD19-expressing B-lineage tumour cells and mediate T-cell activation, proliferation and cytotoxic killing.

General use cases

  • Treatment of adults with specified large B-cell lymphomas, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B, in the treatment settings defined by the current product label.
  • The current US label includes selected earlier-line and later-line settings; primary central nervous system lymphoma is not an indicated use.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Lisocabtagene Maraleucel PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Lisocabtagene Maraleucel Permitted Daily Exposure (PDE) report (the Lisocabtagene Maraleucel PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Lisocabtagene Maraleucel Occupational Exposure Limit (OEL) report (the Lisocabtagene Maraleucel OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.